Novo Nordisk: Full Kitchen Sink Reset Or Another Shoe Yet To Drop? [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
Hims's $49-per-month oral Wegovy copycat could have significantly intensified self-pay competition, but the way events unfolded ultimately provided a modest tailwind for Novo instead. 2025 results were mixed: sales slightly beat and grew +6% YoY, while net income came in a touch below expectations. Global GLP-1 volume leadership remains intact. NVO's near-term focus is launching higher-dose semaglutide (7.2 mg) and advancing CagriSema to match Eli Lilly's efficacy, aiming to regain momentum. NVO's 2026 outlook reflects deeper-than-expected U.S. price declines, driven by channel mix, MFN agreements, and a muted but manageable LOE impact in international markets. Victor Golmer/iStock Editorial via Getty Images Intro I think it's fair to say that it's been a really tough time lately for Novo Nordisk A/S ( NVO ) shareholders. It looked as if the oral Wegovy approval just days This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivativ
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk plans Wegovy vials amid obesity-drug competition [Yahoo! Finance]Yahoo! Finance
- West Pharma forecasts 2026 profit above estimates on strong demand for drug components [Yahoo! Finance Canada]Yahoo! Finance Canada
- Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk A/S (NYSE:NVO) was upgraded by analysts at Jefferies Financial Group Inc. from an "underperform" rating to a "hold" rating.MarketBeat
- Novo CEO blasts ‘mass compounding' of GLP-1 drugs as safety battle escalates [FOX Business Network]FOX Business Network
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/11/26 - Form 6-K
- 2/10/26 - Form 6-K
- 2/9/26 - Form 6-K
- NVO's page on the SEC website